Rice Hall James & Associates LLC Cuts Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Rice Hall James & Associates LLC decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 58,968 shares of the specialty pharmaceutical company’s stock after selling 1,407 shares during the quarter. Rice Hall James & Associates LLC’s holdings in ANI Pharmaceuticals were worth $3,260,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the business. Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of ANI Pharmaceuticals by 3.9% in the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after buying an additional 300 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after buying an additional 310 shares in the last quarter. New York State Teachers Retirement System increased its position in shares of ANI Pharmaceuticals by 1.7% in the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after buying an additional 394 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after buying an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Down 0.2 %

ANI Pharmaceuticals stock opened at $58.82 on Wednesday. The stock has a market cap of $1.24 billion, a PE ratio of -106.94 and a beta of 0.74. The stock has a 50-day moving average price of $56.98 and a 200 day moving average price of $58.23. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,781 shares of company stock valued at $2,465,372. Insiders own 12.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ANIP shares. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Truist Financial raised their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.